NCT05476887View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 25, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

February 28, 2025

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

KP104

KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.

Trial Locations (4)

Unknown

Peking Union Medical College Hospital, Beijing

Jiangsu Province Hospital, Nanjing

Chinese Academy of Medical Sciences Peking Union Medical College - Institute of Hematology Blood Diseases Hospital, Tianjin

Henan Cancer Hospital, Zhengzhou

Sponsors
All Listed Sponsors
lead

Kira Pharmacenticals (US), LLC.

INDUSTRY